Physician profile
Victor Lyapis
NPI 1760407936
$36,655.50
in general payments reported to CMS, 2019-2025
59 companies · $4,944 in 2025
The $4,944 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,730 · 2020: $4,369 · 2021: $6,628 · 2022: $6,408 · 2023: $5,723 · 2024: $4,853 · 2025: $4,944.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K · Education: $52.63.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $15,467.32 |
| Education | $52.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,213.97 | 2019-2025 | |
| Kowa Pharmaceuticals America, INC. | $3,092.92 | 2019-2025 | Zoryve, Livalo, Seglentis |
| Novo Nordisk INC | $2,706.24 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $2,678.71 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,455.82 | 2019-2025 | Xifaxan, Trulance |
| Allergan, INC. | $1,918.16 | 2019-2022 | |
| Glaxosmithkline, LLC. | $1,794.87 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $1,537.64 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,399.52 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $1,226.38 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,159.79 | 2019-2024 | Trintellix |
| Sumitomo Pharma America, INC. | $1,110.39 | 2023-2025 | Gemtesa |
| Nestle Healthcare Nutrition INC. | $1,051.55 | 2020-2023 | |
| Pfizer INC. | $1,025.87 | 2019-2025 | |
| Amgen INC. | $954.55 | 2019-2025 | Repatha, Otezla, Prolia |
Show all 59 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $934.03 | 2020-2025 | Nexletol |
| Sunovion Pharmaceuticals INC. | $875.82 | 2021-2022 | |
| Ironwood Pharmaceuticals, INC | $689.21 | 2019-2024 | Linzess |
| Amarin Pharma, INC. | $677.88 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $397.52 | 2019-2022 | |
| Madrigal Pharmaceuticals | $394.63 | 2024-2025 | Rezdiffra, Resmetirom |
| Astellas Pharma US INC | $391.95 | 2019-2023 | Veozah, Myrbetriq |
| Novartis Pharmaceuticals Corporation | $389.03 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $387.51 | 2019-2025 | Verquvo, Belsomra |
| E.R. Squibb & Sons, L.L.C. | $371.17 | 2019-2025 | Eliquis, Camzyos |
| Eisai INC. | $322.80 | 2020-2022 | |
| Biohaven Pharmaceuticals, INC. | $279.27 | 2021 | |
| Aimmune Therapeutics, INC. | $252.71 | 2024-2025 | Zenpep |
| Almatica Pharma LLC | $234.27 | 2023-2024 | Loreev Xr, Gralise |
| Medtronic, INC. | $217.37 | 2021-2025 | Symplicity G3 |
| Biohaven Pharmaceutical Holding Company LTD. | $147.77 | 2022 | |
| Scilex Pharmaceuticals INC. | $145.81 | 2019-2024 | Ztlido |
| Idorsia Pharmaceuticals US INC | $141.39 | 2023-2024 | Quviviq |
| Phathom Pharmaceuticals, INC. | $108.19 | 2024-2025 | Voquezna |
| Redhill Biopharma INC. | $96.26 | 2022-2023 | Aemcolo, Talicia, Movantik |
| Merz North America, INC. | $75.49 | 2024-2025 | |
| Lundbeck LLC | $74.35 | 2023-2024 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $73.14 | 2024-2025 | Rexulti |
| Ardelyx, INC. | $72.23 | 2023 | Ibsrela |
| Arbor Pharmaceuticals, INC. | $64.09 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $49.87 | 2020-2021 | |
| Currax Pharmaceuticals LLC | $47.51 | 2023-2024 | Contrave, Nexlizet, Nexletol |
| Smith+Nephew, INC. | $44.94 | 2021-2024 | Collagenase Santyl |
| Nalpropion Pharmaceuticals LLC | $34.81 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $32.62 | 2025 | Caplyta |
| Regeneron Healthcare Solutions, INC. | $27.39 | 2019 | |
| Azurity Pharmaceuticals, INC. | $27.31 | 2025 | Edarbi |
| Vivus LLC | $27.04 | 2025 | Pancreaze |
| Alfasigma USA, INC. | $26.31 | 2020 | |
| Xeris Pharmaceuticals, INC. | $24.81 | 2025 | Gvoke Hypopen |
| Viiv Healthcare Company | $23.49 | 2023 | Apretude |
| Fidia Pharma USA INC. | $23.11 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $22.61 | 2021 | |
| Dexcom, INC. | $22.24 | 2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $21.47 | 2024 | Cologuard Collection Kit |
| Ibsa Pharma INC. | $17.39 | 2022 | |
| Galderma Laboratories, L.P. | $15.68 | 2025 | |
| Shield Therapeutics INC | $15.14 | 2025 | |
| Medicure Pharma INC. | $11.49 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Victor Lyapis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.